Viemed Healthcare Inc Revenue Growth Rates (VMD), Current and Historic Growth - CSIMarket
CSIMarket
 


Viemed Healthcare Inc   (NASDAQ: VMD)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

VMD's Revenue Growth by Quarter and Year

Viemed Healthcare Inc 's Revenue results by quarter and year




VMD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 78.10
1st Quarter March 75.41
FY 153.51

VMDs Annual Revenue
Viemed Healthcare Inc 's Revenue in the fiscal year 2025 $ 270.28 millions
Viemed Healthcare Inc 's Revenue in the fiscal year 2024 $ 224.26 millions
Viemed Healthcare Inc 's Revenue in the fiscal year 2023 $ 183.01 millions
Viemed Healthcare Inc 's Revenue in the fiscal year 2022 $ 138.83 millions
Viemed Healthcare Inc 's Revenue in the fiscal year 2021 $ 117.06 millions




VMD Revenue second quarter 2026 Y/Y Growth Comment
Viemed Healthcare Inc achieved in the second quarter 2026, above Company average Revenue growth of 23.85% year on year, to $ 78.10 millions.

Looking into second quarter 2026 results within Healthcare Facilities industry 23 other companies have achieved higher Revenue growth. While Viemed Healthcare Inc ' s Revenue rise of 23.85% ranks overall at the positon no. 2246 in the second quarter 2026.




VMD Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter December - 25.5 % 19.63 % 35.27 %
3rd Quarter September - 23.98 % 17.41 % 38.14 %
2nd Quarter June 23.85 % 14.72 % 26.92 % 30.02 %
1st Quarter March 27.53 % 16.88 % 27.88 % 22.63 %
FY   - 20.52 % 22.54 % -

Financial Statements
Viemed Healthcare Inc 's second quarter 2026 Revenue $ 78.10 millions VMD's Income Statement
Viemed Healthcare Inc 's second quarter 2025 Revenue $ 63.06 millions Quarterly VMD's Income Statement


VMD Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter December - 5.94 % 4.66 % 2.71 %
3rd Quarter September - 14.03 % 5.51 % 14.06 %
2nd Quarter June 3.56 % 6.65 % 8.66 % 9.48 %
1st Quarter March -1.01 % -2.59 % -0.3 % 5.47 %
FY (Year on Year)   - 20.52 % 22.54 % -




Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #24
Healthcare Sector #328
Overall #2246

Revenue Y/Y Growth Statistics
High Average Low
57.42 % 23.46 % -11.05 %
(Dec 31 2020)   (Mar 31 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #24
Healthcare Sector #328
Overall #2246
Revenue Y/Y Growth Statistics
High Average Low
57.42 % 23.46 % -11.05 %
(Dec 31 2020)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Viemed Healthcare Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
80.01 % 6.23 % -21.95 %
(Jun 30 2020)  


VMD's II. Quarter Q/Q Revenue Comment
Viemed Healthcare Inc achieved in the II. Quarter 2026 below company average Revenue growth of 3.56% quarter on quarter, to $ 78.10 millions.

Within Healthcare Facilities industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Viemed Healthcare Inc 's Revenue growth quarter on quarter, overall rank is 1287.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #12
Healthcare Sector #184
Overall #1287
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #12
Healthcare Sector #184
Overall #1287
Revenue Q/Q Growth Statistics
High Average Low
80.01 % 6.23 % -21.95 %
(Jun 30 2020)  


VMD's II. Quarter Q/Q Revenue Comment
Viemed Healthcare Inc achieved in the II. Quarter 2026 below company average Revenue growth of 3.56% quarter on quarter, to $ 78.10 millions.

Within Healthcare Facilities industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Viemed Healthcare Inc 's Revenue growth quarter on quarter, overall rank is 1287.


Viemed Healthcare Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending
(Mar 31 2026)
12 Months Ending
(Dec 31 2025)
12 Months Ending
(Sep 30 2025)
12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 301.61 $ 286.56 $ 270.28 $ 254.79 $ 240.88
Y / Y Revenue Growth (TTM) 25.21 % 23.1 % 20.52 % 18.9 % 17.11 %
Year on Year Revenue Growth Overall Ranking # 1000 # 171 # 286 # 116 # 256
Seqeuential Revenue Change (TTM) 5.25 % 6.03 % 6.08 % 5.77 % 3.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 2250 # 734 # 1322 # 1556 # 1179


Cumulative Revenue growth Comment
Viemed Healthcare Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 25.21% year on year, to $ 302 millions if the fiscal year would have ended in Jun 30 2026.
Viemed Healthcare Inc 's trailing twelve months Revenue growth was higher than company's average 23.73% and higher than 23.1% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 5.25 % from $286.57 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at23.73%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 5.25 % increase from $286.57 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 192 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 171 to 1000.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 24
Healthcare Sector # 193
Overall # 1000

Revenue TTM Y/Y Growth Statistics
High Average Low
63.61 %
23.73 %
-11.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 328
S&P 500 # 2250
Cumulative Revenue growth Comment
Viemed Healthcare Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 25.21% year on year, to $ 302 millions if the fiscal year would have ended in Jun 30 2026.
Viemed Healthcare Inc 's trailing twelve months Revenue growth was higher than company's average 23.73% and higher than 23.1% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 5.25 % from $286.57 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at23.73%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 5.25 % increase from $286.57 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 192 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 171 to 1000.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 24
Healthcare Sector # 193
Overall # 1000

Revenue TTM Y/Y Growth Statistics
High Average Low
63.61 %
23.73 %
-11.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 328
S&P 500 # 2250




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VMD's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions


About Viemed Healthcare Inc Revenue Growth Rates (VMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Viemed Healthcare Inc (CIK 1729149).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001729149-26-000042
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Viemed Healthcare Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.